Oxford Immunotec Global PLC (OXFD) Set to Announce Quarterly Earnings on Tuesday
Oxford Immunotec Global PLC (NASDAQ:OXFD) will issue its quarterly earnings data before the market opens on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. Oxford Immunotec Global PLC’s revenue was up 35.9% on a year-over-year basis. On average, analysts expect Oxford Immunotec Global PLC to post $-1.56 EPS for the current fiscal year and $-0.9 EPS for the next fiscal year.
Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 15.98 on Tuesday. The stock’s market cap is $368.75 million. Oxford Immunotec Global PLC has a one year low of $11.88 and a one year high of $19.51. The stock’s 50 day moving average price is $16.23 and its 200 day moving average price is $15.73.
ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (OXFD) Set to Announce Quarterly Earnings on Tuesday” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/24/oxford-immunotec-global-plc-oxfd-set-to-announce-quarterly-earnings-on-tuesday.html.
In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Peter Edwardson sold 9,739 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $16.14, for a total value of $157,187.46. Following the transaction, the chief operating officer now owns 92,905 shares of the company’s stock, valued at approximately $1,499,486.70. The disclosure for this sale can be found here. Insiders have sold a total of 90,110 shares of company stock valued at $1,523,514 in the last 90 days. 8.11% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Oxford Immunotec Global PLC stock. Vanguard Group Inc. raised its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 5.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,043 shares of the company’s stock after buying an additional 3,507 shares during the quarter. Vanguard Group Inc. owned about 0.30% of Oxford Immunotec Global PLC worth $1,161,000 as of its most recent SEC filing. 79.21% of the stock is owned by hedge funds and other institutional investors.
OXFD has been the topic of several recent analyst reports. Cowen and Company reissued a “buy” rating and set a $22.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. BTIG Research started coverage on Oxford Immunotec Global PLC in a report on Thursday, September 28th. They set a “buy” rating and a $21.00 price target for the company. Zacks Investment Research upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $26.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $22.00.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.